A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients

OBJECTIVE: To assess the pharmacodynamic effects of sifalimumab, an investigational anti-IFN-α monoclonal antibody, in the blood and muscle of adult dermatomyositis and polymyositis patients by measuring neutralisation of a type I IFN gene signature (IFNGS) following drug exposure. METHODS: A phase...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Principais autores: Higgs, Brandon W, Zhu, Wei, Morehouse, Chris, White, Wendy I, Brohawn, Philip, Guo, Xiang, Rebelatto, Marlon, Le, Chenxiong, Amato, Anthony, Fiorentino, David, Greenberg, Steven A, Drappa, Jorn, Richman, Laura, Greth, Warren, Jallal, Bahija, Yao, Yihong
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2014
Assuntos:
Basic and Translational Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3888620/
https://ncbi.nlm.nih.gov/pubmed/23434567
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2012-202794
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados